Nasdaq

Audentes Therapeutics Announces Expansion of AAV Technology Platform and Pipeline with New Development Programs for Duchenne Muscular Dystrophy and Myotonic Dystrophy

Call may be accessed by dialing (833) 659-8620 (U.S.) or (409) 767-9247 (international) and using conference ID# 8879216 Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic ...

Siren Biotechnology Awarded $8M in Non-Dilutive Grant Funding from the California Institute for Regenerative Medicine (CIRM) to Support Clinical Development of SRN-101 in High ...

Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for cancer, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded the Company an $8M ...
Nasdaq

MeiraGTx To Present Clinical Program Update for AAV-hAQP1 Treatment of Radiation-Induced Xerostomia

LONDON and NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company will host a ...
Business Wire

Forge Biologics Selected as an AAV Manufacturing Partner for California Institute for Regenerative Medicine to Help Accelerate Gene Therapy Programs

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics (Forge), a leading manufacturer of genetic medicines, announced today that it has joined the California Institute for Regenerative Medicine’s (CIRM) ...
Seeking Alpha

Abeona Therapeutics Announces Update on AAV Ophthalmology Program

NEW YORK and CLEVELAND, March 14, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (ABEO) today announced three internally developed investigational preclinical gene therapy product candidates from ...
Seeking Alpha

Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

CLEVELAND, May 16, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (ABEO) today announced new data regarding three internally developed preclinical gene therapy product candidates from its ...
Business Insider

Axovant Announces Global Licensing Agreement for AXO-AAV-OPMD Program for Treatment of Oculopharyngeal Muscular Dystrophy and Broader Platform Collaboration with Benitec Biopharma

License grants Axovant worldwide rights to AXO-AAV-OPMD utilizing proprietary Silence-and-Replace technology, which suppresses mutant protein production while restoring expression of functional ...
Business Wire

Forge Biologics Receives Qualified Person (QP) Declaration to Manufacture AAV Gene Therapies to Support European Clinical Programs

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics, a leading manufacturer of genetic medicines, today announced that its manufacturing facility has successfully completed the audits necessary and ...